| 1 陈竺. 全国第三次死因回顾抽样调查报告[M]. 北京:中国协和医科大学出版, 2008:10-17.2 Philip M, Benatar M, Fisher M, et al. Methodological quality of animal studies of neuroprotective agents currency in phase II/III acute ischemic stroke trials[J]. Stroke, 2009, 40:577-581.3 Fisher M, Feuerstein G, Howells DW, et al. Update of the stroke therapy academic industry roundtable preclinical recommendations[J]. Stroke, 2009, 40:2244-2250.4 Dirnagl U, Macleod MR. Stroke research at a road block:the streets from adversity should be paved with meta-analysis and good laboratory practice[J]. Br J Pharmacol, 2009, 157:1154-1156.5 O'Collins VE, Macleod MR, Donnan GA, et al. 1026 experimental treatments in acute stroke[J]. Ann Neurol, 2006, 59:467-477.6 Dallas. Stroke Trials Registry Home Page[DB/OL]. (2012-8-17)[2013-06-01]. http://www. strokecenter. org/trials/. 7 Edward C, Jauch JL, Saver HP, et al. Guidelines for the early management of patients with acute ischemic stroke:a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J]. Stroke, 2013, 44:870-947.8 Ginsberg MD. Neuroprotection for ischemic stroke:past, present and future[J]. Neuropharmacology, 2008, 55:363-389.9 Belayev L, Liu Y, Zhao W, et al. Human albumin therapy of acute ischemic stroke:marked neuroprotective efficacy at moderate doses and with a broad therapeutic window[J]. Stroke, 2001, 32:553-560.10 Palesch YY, Hill MD, Ryckborst KJ, et al. The ALIAS Pilot Trial:a dose-escalation and safety study of albumin therapy for acute ischemic stroke-II:neurologic outcome and efficacy analysis[J]. Stroke, 2006, 37:2107-2114.11 Ginsberg MD, Palesch YY, Hill MD. The ALIAS (ALbumin In Acute Stroke) Phase III randomized multicentre clinical trial:design and progress report[J]. Biochem Soc Trans, 2006, 34(Pt 6):1323-1326.12 Ovbiagele B, Kidwell CS, Starkman S, et al. Neuroprotective agents for the treatment of acute ischemic stroke[J]. Curr Neurol Neurosci Rep, 2003, 3:9-20.13 Meloni BP, Zhu H, Knuckey NW. Is magnesium neuroprotective following global and focal cerebral ischaemia? A review of published studies[J]. Magnes Res, 2006, 19:123-137.14 Saver JL, Kidwell C, Eckstein M, et al. Prehospital neuroprotective therapy for acute stroke:results of the Field Administration of Stroke Therapy-Magnesium (FAST-MAG) pilot trial[J]. Stroke, 2004, 35:e106-e108.15 Mees SMD, Algra A, Vandertop WP, et al. Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2):A randomised placebo-controlled trial[J]. Lancet, 2012, 380:44-49.16 Yang L, Deng Y, Xu S, et al. In vivo pharmacokinetic and metabolism studies of ginsenoside R[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2007, 854:77-84.17 谢填, 张琛, 史明, 等. 人参皂甙Rd在脑缺血中的保护作用[J]. 神经解剖学杂志, 2012, 29:510-512.18 Ye R, Zhang X, Kong X, et al. Ginsenoside Rd attenuates mitochondrial dysfunction and sequential apoptosis after transient focal ischemia[J]. J Neuroscience, 2011, 178:169-180. 19 Ye RD, Yang QZ, Kong XW, et al. Ginsenoside Rd attenuates early oxidative damage and sequential inflammatory response after transient focal ischemia in rats[J]. Neurochem Int, 2011, 58:391-398.20 Zeng X, Deng YH, Feng Y, et al. Pharmacokinetics and safety of ginsenoside Rd following a single or multiple intravenous dose in healthy Chinese volunteers[J]. J Clin Pharmacol, 2010, 50:285-292.21 Liu X, Xia J, Wang L, et al. Efficacy and safety of ginsenoside-Rd for acute ischaemic stroke:a randomized, double-blind, placebo controlled, phase II multicenter trial[J]. J Eur J Neurol, 2009, 16:569-575.22 张琛, 赵钢. 人参皂苷Rd的药理作用研究进展[J]. 中国新药杂志, 2011, 20:953-958.23 Kornau HC, Schenker LT, Kennedy MB, et al. Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95[J]. Science, 1995, 269:1737-1740.24 Sattler R, Xiong Z, Lu WY, et al. Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein[J]. Science, 1999, 284:1845-1848.25 Aarts M, Liu Y, Liu L, et al. Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions[J]. Science, 2002, 298:846-850.26 Cook DJ, Teves L, Tymianski M. Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain[J]. Nature, 2012, 483:213-217.27 Michael D Hill, Renee H Martin, David Mikulis, et al. Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT):a phase 2, randomised, double-blind, placebo-controlled trial[J]. Lancet Neurol, 2012, 11:942-950.28 Macleod MR, Vander Worp HB, Sena ES, et al. Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality[J]. Stroke, 2008, 39:2824-2829.29 Lo EH, Dalkara T, Moskowitz MA. Mechanisms, challenges and opportunities in stroke[J]. Nat Rev Neurosci, 2003, 4:399-414.30 Manjila S, Masri T, Shams T, et al. Evidence-based review of primary and secondary ischemic stroke prevention in adults:a neurosurgical perspective[J]. Neurosurg Focus, 2011, 115:E1.31 Zhang JH, Badaut J, Tang J, et al. The vascular neural network-a new paradigm in stroke pathophysiology[J]. Nat Rev Neurol, 2012, 8:711-716. |
